Regardless of the macroeconomic environment, we remain focused on applying our well-established, long-term, bottom-up EQV ...

The medicine, Trastuzumab deruxtecan, was already available for some breast and stomach cancers. It has been approved to ...

ACTO, the AI-powered Intelligent Field Excellence (IFE) platform built specifically for life sciences, today announced the ...

Breztri Aerosphere, a triple inhaled therapy, met its primary endpoint of lung function improvement in adults and adolescents with uncontrolled asthma in two phase 3 trials, according to a press ...

Larry Hogan speaks to members of the media at the AstraZeneca facility in Gaithersburg, Md., on Aug. 26, 2024. Larry Hogan ...

"Portugal is very attractive for staff and in terms of talent" - Nathalie von Widdern, country president, AstraZeneca.

AstraZeneca and Daiichi's Enhertu, followed by THP, has shown pCR rate improvement in the randomised DESTINY-Breast11 Phase ...

AstraZeneca (AZN) and Daiichi Sankyo (DSNKY) announce that Enhertu hit the main goal in a Phase 3 trial for early-stage ...

T-DXd plus THP led to significant improvements in pathologic complete response in patients with early-stage, HER2+ breast ...

Less than three weeks after AstraZeneca and Daiichi Sankyo reported positive results for oncology powerhouse Enhertu in a ...

The biggest strategic highlight for Tempus AI Inc. (NASDAQ: TEM) during the first quarter was a multi-million dollar deal to build "the world's largest foundation model for oncology." ...

(Alliance News) - AstraZeneca PLC on Wednesday said it has received positive high-level results from its latest trial evaluating Enhertu in patients with high-risk, locally advanced HER2-positive ...